American Express Announces Plans to Expand Centurion® Lounges in Two Major U.S. Airports and Prepares to Welcome Travelers with New Health and Safety Practices
16.9.2020 16:00:00 EEST | Business Wire | Press release
Today, American Express (NYSE: AXP) announced plans to expand two of its signature Centurion Lounges and introduced The Centurion Lounge Commitment, a set of new health and safety protocols and practices, which will be implemented in all Centurion Lounges as they reopen (some starting in early October). The Centurion Lounge at New York's LaGuardia Airport (LGA) will relocate to a larger location in the brand new Terminal B, and as previously announced, the current Centurion Lounge at Las Vegas’ McCarran International Airport (LAS), will be expanded and redesigned.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005291/en/
Rendering of Centurion Lounge at New York's LaGuardia Airport (Photo: Business Wire)
“The health, safety and comfort of our Card Members and colleagues remains our top priority as we look to expand and reopen our iconic Centurion Lounges around the world,” said Alexander Lee, Vice President Travel Experiences & Benefits. “We believe travel is core to our Card Members’ lifestyles, and like them, we look forward to the day when we can travel the world again - we’re excited to welcome them back into our Centurion Lounges soon.”
Upgrading the Centurion Lounge Experience at LAS and LGA:
Renovations to The Centurion Lounges at New York's LaGuardia Airport and Las Vegas’ McCarran International Airport will be completed in 2021. The expanded lounges will feature a suite of amenities for Card Members to enjoy when they resume traveling.
- The Centurion Lounge at LGA will double in size and relocate to a space post-security within the airport’s brand-new, state-of-the-art Terminal B. The new lounge will feature a family room, additional workspaces, private telephone rooms, and views of the New York City skyline.
- The footprint of the first-ever Centurion Lounge, opened at LAS in 2013, will be expanded from nearly 9,000 square feet to over 13,400 square feet. The newly designed lounge will feature additional multi-purpose areas, new private telephone rooms, newly designed reception and workspace areas and more.
American Express is also working towards opening its newest lounge locations later this year in New York’s John F. Kennedy Airport, London’s Heathrow Airport and Denver International Airport.
Creating a Healthy and Safe Environment with The Centurion Lounge Commitment:
While our Centurion Lounges continue to be closed due to COVID-19, American Express is introducing The Centurion Lounge Commitment to further support the health and safety of Card Members and colleagues when the lounges reopen. According to the Amex Trendex*, a trend report from American Express, nearly 2 in 3 consumers say either health and safety policies and procedures (39%) or flexibility (25%) is most important as they look to book future travel.
Card Members will experience new health and safety practices such as socially distanced seating, reduced capacity, increased cleaning frequency, requirements to wear a face covering when entering the lounge, served food instead of buffets, and more. For a contactless check-in experience, Card Members can download the American Express® App and use the Mobile Check-in Feature. These practices will be re-evaluated on an ongoing basis to take into account Card Members’ needs and the requirements of state and local governments and health authorities. Learn more here: thecenturionlounge.com/reopening.
While some may not be ready to travel today, the Amex Trendex* found over half (56%) of consumers who typically travel domestically anticipate feeling comfortable traveling to a domestic destination within six months. American Express is evaluating when to reopen its Centurion Lounge locations based on several factors, including local COVID-19 case prevalence, and will be taking a phased approach, location by location. The company expects to reopen the Centurion Lounges at Seattle-Tacoma airport and Philadelphia International airport on October 5, 2020, with more locations to follow.
*Amex Trendex
Methodology:
This online poll was conducted by Morning Consult poll between August 18-20, 2020 among a national sample of 2,000 general population travelers with a household income of at least $70K, and defined as adults (18+) who traveled by air at least once in 2019. Results from the survey have a margin of error of plus or minus 2 percentage points.
ABOUT AMERICAN EXPRESS
American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress, instagram.com/americanexpress, linkedin.com/company/american-express, twitter.com/americanexpress, and youtube.com/americanexpress.
Key links to products, services and corporate responsibility information: charge and credit cards, business credit cards, travel services, gift cards, prepaid cards, merchant services, Accertify, InAuth, corporate card, business travel, and corporate responsibility.
ABOUT THE CENTURION LOUNGE
The Centurion Lounge is the signature lounge program within the broader American Express Global Lounge Collection, which includes access to American Express Centurion Lounges, international American Express lounges, Delta Sky Club® for Card Members flying on Delta, Priority PassTM Select Lounges upon enrollment, Airspace Lounges, MAG U.S. Escape Lounges and Plaza Premium Lounges--a total of more than 1,300 lounges across 140 countries and counting.
Access to The Centurion Lounge is complementary and exclusive for Platinum Card Members, Centurion Members and Delta SkyMiles® Reserve Card Members. Platinum Card Members may enter with up to two travel companions at no additional charge. Centurion Members may enter with their immediate family or up to two travel companions. Platinum Card and Centurion Members may purchase access to The Centurion Lounge for additional guests for $50 each guest. Delta SkyMiles® Reserve Card Members may bring up to two guests at a per-visit rate of $50 per person, per location.
Location: Global
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005291/en/
Contact information
AMERICAN EXPRESS
Margot Leeds
Margot.Leeds@aexp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom